Poonawalla Fincorp Q1FY27: consolidated PAT up 391% YoY to ₹308 Cr, NPM expands to 13.2%

Poonawalla Fincorp's consolidated PAT (identical to standalone, since the sole JV contributes nil) came in at ₹307.71 Cr for Q1 FY27, up 391.6% YoY from ₹62.60 Cr and 20.8% QoQ from ₹254.79 Cr. Revenue from operations rose 77.3% YoY and 10.2% QoQ to ₹2,330.22 Cr, with total income at ₹2,336.92 Cr. No specific pre-result sell-side PAT consensus for this quarter could be located, so the print cannot be benchmarked against street numbers; broader coverage found only a post-print 'Buy' consensus and price targets, not a Q1 estimate — vsStreet is marked unknown rather than guessed.

The margin story is the core of the quarter: net margin (company-disclosed, reg 52(4)) expanded to 13.17% from 4.76% a year ago and 12.02% last quarter. The bridge is credit cost and funding cost normalization rather than a one-off — impairment on financial instruments fell to 15.1% of total income (₹353.57 Cr) from 18.3% (₹241.08 Cr) a year ago, and finance costs eased to 39.4% of income from 41.6%, even as both rose in absolute Rupee terms on a larger, QIP-funded book. EPS (basic) grew 338% YoY to ₹3.55 versus PAT's 391.6% growth, reflecting ~13% share-count dilution from the ₹2,500 Cr QIP completed 13 April 2026 (fully deployed per the QIP deviation statement filed alongside these results) and ESOP allotments.

The stock went into the print at ₹459.7, up 7.4% over the past month of trading.

For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 5 consecutive quarters.

Against management's Q4 FY26 guidance of 35-40%+ AUM growth for FY27 and a steady ROA improvement off a 1.81% baseline, the quarter tracks ahead: AUM reached ₹67,054 Cr, up 62.5% YoY and 11.1% QoQ (per the company's investor presentation, not disclosed in this filing), and ROA improved to 1.98%, already ~130bps above the stated baseline — a beat on both counts one quarter into the guided period. Asset quality also improved, with gross Stage-3 at 1.37% and net Stage-3 at 0.70%. The quarter also saw ₹250 Cr of NCDs allotted and an amended insider trading code, both administrative rather than result-moving. No management press release/MD&A text was supplied in the context beyond the filing itself, so this summary relies on the statement and public reporting rather than a direct management quote.